跳至主要内容
临床试验/CTRI/2010/091/001469
CTRI/2010/091/001469招募中2 期

AN OPEN LABEL, RANDOMIZED, MULTICENTRIC, PROSPECTIVE, CLINICAL STUDY TO DETERMINE THE SAFETY AND THEREPEUTIC EFFECTIVENESS OF BONE MARRROW DERIVED ADULT STEM CELLS VIA MULTIPLE ROUTES OF ADMINSTRATION IN THE TREATMENT OF PATIENTS WITH COMPLETE SPINAL CORD INJURY (SCI)

Dr. Himanshu Bansal Foundation0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Be a Male/Female of ages 18 to 65 years
  • 2. Who is properly informed of the nature and risks of the clinical study, who is willing and capable of complying with all clinical study procedures, and has given informed consent in writing prior to entering the clinical study. Subjects who are willing to comply with the study procedure.
  • 3. Be with complete spinal cord injury (ASIA level A)
  • 4. Time between injury and enrollment is greater than or equal 1 month and less than or equal to 1 year
  • 5. Have Platelet count > 100 Thousand/µL at screening
  • 6. Have White Blood Count < 15,000
  • 7. International Normalized Ratio (INR) less than or equal to 1.5
  • 8. Hematocrit < 30% prior to bone marrow aspiration
  • 9. Have the neurological level is between C5 and T10
  • 10. Have complete or partial transaction/damage as shown by MRI

排除标准

  • x. Ongoing Alcohol/ Substance Abuse.
  • x. Intoxication, Intubation, Sedation and Immobilization
  • x.Osteoporosis or low bone mass as determined by medical history or DXA
  • x. Cancer over last 3 years prior to enrollment
  • x. Presence of a primary Hematological disease or any coagulation abnormalities or concomitant treatment with coumarin anti-coagulant
  • x. Implanted Medical Devices like Cardiac Stents, Pace Makers, Bladder Stimulators and Permanent modification of Anatomy
  • x. Uncontrolled Diabetes, Hypertension, Auto Immune Disease, Psychiatric illness, terminal Renal Failure with existing dependence on dialysis and history of Bone Marrow diseases
  • x. Possibility of non-compliance with the protocol.
  • x. Subjects with Syringomyelia, Spinal Stenosis, Plexopathy, Neuropathy, Radiculopathy, Cauda Equina Injury, Myelitis, Demyelination, Ischemia, Severe Spinal Degenerative Pathologies, Ongoing Focal Spinal Cord Compression or anatomically complete lesions
  • x.Longitudinal dimension of injury more than 3 segments
  • x. Women who is pregnant or nursing or of child-bearing potential unwilling to use effective barrier method of contraception for the duration of the study
  • x.No informed consent.
  • x. Signs of Meningitis with Fever (above 39°C)
  • x. Coma or other severe injury or disease
  • x. Penetrating injury
  • x. Unsuitable based on MRI or other factor
  • x. Subjects who have taken Immunosuppressant?s within the last one month

研究者

相似试验

尚未招募
不适用
Open label randomized multicentric parallel group bioequivalence study of Loteprednol etanbonate opthalmic suspension 0.5%
CTRI/2015/08/006077Watson Pharma Pvt Ltd India560
进行中(未招募)
1 期
Extension study of a phase 3 clinical trial to compare the efficacy and safety of Mylan's Insulin Glargine with commercial Insulin Glargine (Lantus®) in patients with type 1 diabetesMedDRA version: 18.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 Diabetes Mellitus
EUCTR2015-004353-40-LVMylan GmbH110
进行中(未招募)
1 期
Extension study of a phase 3 clinical trial to compare the efficacy and safety of Mylan's Insulin Glargine with commercial Insulin Glargine (Lantus®) in patients with type 1 diabetesMedDRA version: 18.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 Diabetes Mellitus
EUCTR2015-004353-40-HUMylan GmbH110
进行中(未招募)
1 期
A phase 3 clinical trial to compare the efficacy and safety of Mylan's Insulin Glargine with commercial Insulin Glargine (Lantus®) in patients with type 1 diabetesMedDRA version: 17.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 Diabetes Mellitus
EUCTR2014-000747-32-SKMYLAN GmbH500
进行中(未招募)
1 期
A phase 3 clinical trial to compare the efficacy and safety of Mylan's Insulin Glargine with commercial Insulin Glargine (Lantus®) in patients with type 1 diabetesMedDRA version: 19.0Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 Diabetes Mellitus
EUCTR2014-000747-32-DEMYLAN GmbH500
A Clinical Trial to study the safety &amp;... | 临床试验